NNVC beat EPS expectations by 17.44%
May 27, 2024, 4:33 PM
-37.79%
What does NNVC do
NanoViricides, Inc., a development stage company based in Shelton, Connecticut, focuses on creating nanomedicine drugs targeting viruses, with key candidates NV-CoV-2 and NV-CoV-2-R for COVID-19 treatment. Established in 2004, the company employs seven people and develops drugs for various viral diseases, including RSV, Herpes, and influenza types.
NanoViricides (NNVC) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, NanoViricides's actual EPS was -$0.16, beating the estimate of -$0.19 per share, resulting in a 17.44% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.